IP Library › Granted Patent US 12,570,599
Granted Patent B2
US 12,570,599 · App. 17/618,585 · Granted Mar 10, 2026

Process for preparing acyl-capped 3-hydroxycarboxylic acids and their salts and esters

Inventors: Dirk Lochmann (Witten, DE); Sebastian Reyer (Witten, DE); Michael Stehr (Witten, DE)
Assignee: KetoLipix Therapeutics GmbH
C07C69/716C07C67/02C12N9/20C12P7/62
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,570,599
App. No.
17/618,585
Granted
Mar 10, 2026
Kind
B2
Abstract

The invention relates to a method for producing optionally functionalized acyl-capped (acyl-blocked) 3-hydroxybutyric acids and their salts and esters as well as to the products thus obtained and their use.

Claims (21)

1 . A functionalized acyl-capped 3-hydroxybutyric ester,

wherein the functionalized acyl-capped 3-hydroxybutyric ester corresponds to general formula (III″)

CH 3 —CH(OR 3 )—CH 2 —C(O)OR 4   (III″)

wherein, in the general formula (III″), the radical R 3 represents a radical CH 3 —C(O)—CH 2 —C(O)— and the radical R 4 represents a linear or branched, saturated or mono- or polyunsaturated aliphatic C 6 -C 30 -alkyl radical.

2 . The functionalized acyl-capped 3-hydroxybutyric ester according to claim 1 ,

wherein the functionalized acyl-capped 3-hydroxybutyric ester corresponds to general formula (III″)

CH 3 —CH(OR 3 )—CH 2 —C(O)OR 4   (III″)

wherein, in the general formula (III″), the radical R 3 represents a radical CH 3 —C(O)—CH 2 —C(O)— and the radical R 4 represents a linear or branched, saturated or mono- or polyunsaturated aliphatic C 10 -C 30 -alkyl radical.

3 . The functionalized acyl-capped 3-hydroxybutyric ester according to claim 1 ,

wherein the functionalized acyl-capped 3-hydroxybutyric ester corresponds to general formula (III″)

CH 3 —CH(OR 3 )—CH 2 —C(O)OR 4   (III″)

wherein, in the general formula (III″), the radical R 3 represents a radical CH 3 —C(O)—CH 2 —C(O)— and the radical R 4 represents a linear or branched, saturated or mono- or polyunsaturated aliphatic C 10 -C 24 -alkyl radical.

4 . A mixture comprising at least two different functionalized acyl-capped 3-hydroxybutyric esters, as defined in claim 1 .

5 . A pharmaceutical composition comprising at least one functionalized acyl-capped 3-hydroxybutyric ester, as defined in claim 1 .

6 . The pharmaceutical composition according to claim 5 ,

wherein the pharmaceutical composition is a drug or medicament.

7 . A food or a food product comprising at least one functionalized acyl-capped 3-hydroxybutyric ester, as defined in claim 1 .

8 . A functionalized acyl-capped 3-hydroxybutyric ester,

wherein the functionalized acyl-capped 3-hydroxybutyric ester corresponds to general formula (III″)

CH 3 —CH(OR 3 )—CH 2 —C(O)OR 4   (III″)

wherein, in the general formula (III″), the radical R 3 represents a radical CH 3 —C(O)—CH 2 —C(O)— and the radical R 4 represents a linear or branched, saturated or mono- or polyunsaturated aliphatic C 10 -C 30 -alkyl radical.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2025
From: LOCHMANN, DIRK; REYER, SEBASTIAN; STEHR, MICHAEL
To: IOI OLEO GMBH
Reel/Frame 070623/0994 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2023
From: IOI OLEO GMBH
To: KETOLIPIX THERAPEUTICS GMBH
Reel/Frame 062821/0810 →
Continuity (1)
Related Publication 20220315520A1 · Oct 6, 2022
References Cited (10)
US 7691854B2 · Gielen-Haertwig et al. · 2010 [cited by applicant]
WO WO2018115158A1 · 2018 [cited by examiner]
WO 2018226732 · 2018 [cited by applicant]
Stubbs et al. “On the metabolism of exogenous ketones in humans.” Frontiers in physiology 8 (2017): 848 (Year: 2017). [cited by examiner]
Irby et al. “Lipid-drug conjugate for enhancing drug delivery.” Molecular pharmaceutics 14, No. 5 (2017): 1325-1338 (Year: 2017). [cited by examiner]
Schmidt et al., “Katalytische Hydrierung und Hydrokupplung von Acetessigsauresamiden und-estem mit dem Clusteranion [H3Ru4(CO)12]—als Katalysator”, Journal of Organometallic Chemistry, Jan. 1, 1988, Seiten 379-384. [cited by applicant]
Navarro et al., “Tuning Diketodioxinone Reactivity: Biomimetic Synthesis of the Resorcylate Antibiotic Fungal Metabolites ent -W1278A, -B, and -C, Using Iterative Aromatization Reactions”, Journal of Organic Chemistry, … [cited by applicant]
Sridharan et al., “Mid and High-Yielding Synthesis of [beta]-Keto Esters and [beta]-Ketoamides”, Synthesis, Bd. 2010, Nr. 06, Mar. 1, 2010, Seiten 1053-1057, XP055658643. [cited by applicant]
Florian et al., “The control of Novozym 435 chemoselectivity and specificity by the solvents in acylation reactions of amino-alcohols”, Journal of Molecular Catalysis B: Enzymatic, Bd. 95, Seiten 99-110. [cited by applicant]
Wu et al., “Advances in lipase-catalyzed reactions in solvent-free systems”, Journal of Molecular Catalysis (China), vol. 20, Issue No. 6, pp. 597-603. [cited by applicant]